NBC News Reports History Being Made as Legalization For Colorado and Washington State Optimistically Impacts Growth For Cannabis Science's New Drug Development Programs and State-by-State Medicinal Initiatives
Election Night Success for President Obama and Cannabis Science's Medicinal Programs
COLORADO SPRINGS, Colo., Nov. 7, 2012 /PRNewswire/ -- Cannabis Science Inc., (CBIS) is pleased to see the support of freedom, and science demonstrated by the voters on Election Day along side the re-election of President Obama, History was made for the citizens of Colorado and Washington who clearly voiced their desire to decriminalize the use of cannabis by adults.
NBC News reported; Voters in Colorado and Washington on Tuesday approved measures allowing adults to use marijuana for any purpose, NBC News projected, marking an historic turning point in the slow-growing acceptance of marijuana usage.
Oregon voters decided on similar initiatives to those passed in Washington and Colorado, which would allow marijuana use for any individual over the age of 21, but it seems to have been defeated in Oregon.
Voters in Washington state and Colorado appear to have voted "yes" on measures that would legalize the sale of pot to adults, without the need for a doctor's prescription. (The final votes are still being counted.) And earlier Tuesday evening, voters in Massachusetts overwhelmingly approved the measure to allow the use of medical marijuana.
The efforts of Cannabis Science to medicinalize cannabis with CSTATI-1 for Karposi's Sarcoma Cancer and CS-S/BCC-1 for Basil Squelioma Cancer, provides an opportunity for federal officials to embrace both modern science, and the newly demonstrated will of the electorate, for the betterment of mankind.
About CS-TATI-1
Cannabis Science's research of CS-TATI-1 will be targeted to newly diagnosed patients infected with drug resistant virus, treatment experienced patients with drug-resistant HIV strains, and those intolerant of currently available therapies. Cannabis Science will be pursuing a wide range of NIH based Federal Research Programs such as RO1's, PO1's and SBIRS which exist to support preclinical development of target validation and proof of concept studies. These studies will be implemented through collaborations with leading scientific institutions. Cannabis Science will also be pursuing other clinical research collaborations including the AIDS Clinical Trials Groups (ACTG), the Canadian AIDS Trial Network (CATN) and the European AIDS Trial Network (EATN).
About CS-S/BCC-1
Cannabis Science is currently working to develop preclinical investigations of CS-S/BCC-1 treatment of basal and squamous cell carcinomas. The Company has begun preclinical investigations, which are being initiated in Europe for Squamous/Basal Cell carcinomas and Kaposi's sarcoma based on inhibition of carcinogenicity utilizing cannabinoids that have been demonstrated in recent studies to significantly affect tumor necrosis.
About Cannabis Science, Inc.
Cannabis Science, Inc. is conducting cannabinoid research and development for unmet medical needs. The Company works with leading experts in new drug development, medicinal characterization, and clinical research to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. Cannabis Science is currently working with CBR International to develop a Pre-IND Application to the FDA that focuses on the transdermal delivery of CS-TATI-1 topical cannabis-based preparations for the treatment of basal and squamous cell carcinomas. Recent presentations at AIDS 2012 and The International Conference on Antiviral Research have provoked federal research interest in the development of CS-TATI-1.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Contact:
Cannabis Science, Inc.
President and CEO
Dr. Robert J. Melamede, 888-889-0888
[email protected]
or
VP of Investor Relations
Robert Kane, 561-234-6929
[email protected]
www.cannabisscience.com
SOURCE Cannabis Science, Inc.
Share this article